Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 6:46 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 793–816 of 18,744 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Phase I Clear all

Conditions: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Oral Etoposide, Oral 9-Nitrocamptothecin; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2003
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Small Cell Lung Cancer ( SCLC ), Transformed Small Cell Lung Cancer
Interventions: Lurbinectedin, Osimertinib; Drug
Lead sponsor: Misty Shields; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2029
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Hepatic Complications, Malignant Neoplasm
Interventions: bortezomib, pharmacological study; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 3
States / cities: Duarte, California • Baltimore, Maryland • Detroit, Michigan

Conditions: Leukemia, Multiple Myeloma and Plasma Cell Neoplasm
Interventions: recombinant interferon alfa, rituximab; Biological
Lead sponsor: Hoag Memorial Hospital Presbyterian; Other
Eligibility: Not listed
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 1999
U.S. locations: 3
States / cities: Newport Beach, California • Knoxville, Tennessee • Bryan, Texas

Conditions: HIV Infections
Interventions: Dapivirine gel; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Glioblastoma, MGMT-Unmethylated Glioblastoma
Interventions: Microtubule-Targeted Agent BAL101553, Radiation Therapy; Drug · Radiation
Lead sponsor: Basilea Pharmaceutica; Industry
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 8
States / cities: Birmingham, Alabama • Baltimore, Maryland • Boston, Massachusetts + 5 more

Conditions: Metastatic Breast Cancer
Interventions: Dendritic Cell Vaccination; Biological
Lead sponsor: Southern Cancer Center; Other
Eligibility: 18 Years to 85 Years · Female only
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2015
U.S. locations: 1
States / cities: Mobile, Alabama

Conditions: Palmar-Plantar Erythrodysesthesia, Breast Cancer
Interventions: Cream, 0.1% Uracil Cream; Drug
Lead sponsor: Nanometics (d.b.a. PHD Biosciences); Industry
Eligibility: 18 Years and older · Female only
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 6
States / cities: Birmingham, Alabama • Palm Springs, California • Evansville, Indiana + 3 more

Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia
Interventions: Lenalidomide, Fludarabine, Rituximab; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia, in Relapse
Interventions: Cytokine Induced Memory-Like Natural Killer Cells, Atezolizumb, CIML-NK cell therapy; Biological
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Mucopolysaccharidosis IIIB
Interventions: JR-446; Drug
Lead sponsor: JCR Pharmaceuticals Co., Ltd.; Industry
Eligibility: Up to 5 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 3
States / cities: Oakland, California • Pittsburgh, Pennsylvania • Fairfax, Virginia

Conditions: Non-infectious, Non-necrotizing Anterior Scleritis
Interventions: Dexamethasone Phosphate Ophthalmic Solution (EGP-437), Dexamethasone phosphate ophthalmic solution; Drug
Lead sponsor: John Kempen; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 6
States / cities: San Francisco, California • Miami, Florida • Baltimore, Maryland + 3 more

Conditions: Drug Interactions
Interventions: BIIB074, OC (ethinyl estradiol and levonorgestrel); Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Daytona Beach, Florida

Conditions: Healthy
Interventions: Palbociclib alone, Palbociclib + Rabeprazole; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: South Miami, Florida

Conditions: Advanced Solid Tumors
Interventions: CB-5083; Drug
Lead sponsor: Cleave Biosciences, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 6
States / cities: Scottsdale, Arizona • Los Angeles, California • San Francisco, California + 3 more

Conditions: Advanced Solid Tumors
Interventions: Epofolate; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Cancer, Metastasis, Metastatic Cancer, Brain Metastases, Brain Metastases, Adult
Interventions: Azeliragon, Stereotactic radiosurgery, Corticosteroid; Drug · Radiation
Lead sponsor: Baptist Health South Florida; Other
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Bacterial Infections.
Interventions: Dalbavancin; Drug
Lead sponsor: Durata Therapeutics Inc., an affiliate of Allergan plc; Industry
Eligibility: 3 Months to 11 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 10
States / cities: Little Rock, Arkansas • San Diego, California • Hartford, Connecticut + 7 more

Conditions: Relapsed, Diffuse Large B-cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
Interventions: Betalutin; Drug
Lead sponsor: Nordic Nanovector; Industry
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 3
States / cities: San Diego, California • San Francisco, California • Miami, Florida

Conditions: Multisystem Inflammatory Syndrome in Children
Interventions: Human Cord Tissue Mesenchymal Stromal Cells (hCT-MSCs); Biological
Lead sponsor: Joanne Kurtzberg, MD; Other
Eligibility: 18 Years to 20 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 3
States / cities: Atlanta, Georgia • Westchester, New York • Durham, North Carolina

Conditions: Brain and Central Nervous System Tumors
Interventions: therapeutic autologous dendritic cells; Biological
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 1 Year to 18 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Healthy Volunteer
Interventions: BIIB122, Rabeprazole; Drug
Lead sponsor: Biogen; Industry
Eligibility: 30 Years to 80 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Hepatitis C, Non-Alcoholic Fatty Liver Disease
Interventions: Placebo, Silymarin; Drug
Lead sponsor: National Center for Complementary and Integrative Health (NCCIH); NIH
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 5
States / cities: Boston, Massachusetts • Chapel Hill, North Carolina • Philadelphia, Pennsylvania + 1 more

Conditions: Follicular Lymphoma
Interventions: Bexxar, Low Dose Methotrexate; Drug
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Search by objective public record fields.

Combination Therapy With Oral 9-Nitrocamptothecin & Oral Etoposide

Lurbinectedin With Osimertinib in Transformed Small Cell Lung Cancer

Bortezomib in Treating Patients With Advanced Cancer and Liver Dysfunction

Monoclonal Antibody Therapy or Biological Therapy in Treating Patients With Chronic Lymphocytic Leukemia or Multiple Myeloma in Remission After Chemotherapy

Pharmacokinetic Study of Dapivirine Gel Administered Rectally to HIV-1 Seronegative Adults

Microtubule-Targeted Agent BAL101553 and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma

A Phase I Cancer Vaccine Study for Patients With Metastatic Breast Cancer

Study of 0.1% Uracil Topical Cream (UTC) for the Prevention of Hand-Foot Syndrome

Dose Escalation Study of Revlimid With Fludarabine-Rituximab for CLL/SLL

A Study of Natural Killer Cells in Combination With Atezolizumab in People With Acute Myelogenous Leukemia

A Phase I/II Trial of JR-446 in Mucopolysaccharidosis Type IIIB (MPS IIIB)

Iontophoresis Delivery of Dexamethasone Phosphate for Non-infectious, Non-necrotizing Anterior Scleritis, Phase 1 Dose-varying Study

A Drug Interaction Study of BIIB074 and an Oral Contraceptive Regimen

Drug Interaction Study To Investigate The Potential Effect Of Proton Pump Inhibitor On The Pharmacokinetics Of Palbociclib (PD-0332991)

A Phase 1 Study Evaluating CB-5083 in Subjects With Advanced Solid Tumors

A Phase 1/2 Study of Epofolate (BMS-753493) in Subjects With Advanced Cancer (Schedule 2)

Effect of Azeliragon Combined With Stereotactic Radiation Therapy in Patients With Brain Metastases

A Single Dose Study To Investigate The Pharmacokinetics and Safety Of Dalbavancin In Hospitalized Children Aged 3 Months to 11 Years.

Study of Betalutin for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma (LYMRIT-37-05)

Infusions of Mesenchymal Stromal Cells in Children With Multisystem Inflammatory Syndrome

Vaccine Therapy in Treating Young Patients Who Are Undergoing Surgery for Malignant Glioma

A Study to Assess the Potential for Gastric-pH Dependent Drug-Drug Interactions of BIIB122 With a Proton Pump Inhibitor in Healthy Participants

Phase I Trial of Silymarin for Chronic Liver Diseases

Trial of Low-Dose Methotrexate and I 131 Tositumomab for Previously Untreated, Advanced-Stage, Follicular Lymphoma